Although intralesional injection of GM-CSF increases the numbers of and activates DC and T cells in the tumor microenvironment, its clinical usage has been limited because finding tumors which are accessible for injection and achieving a systemic immune response in these patients is difficult (97). This evidence concerns the gene CSF2 and neoplasm.